Summary
Cardinal Health Inc. reported solid revenue growth in the third quarter of fiscal year 2024, with total revenue increasing by 9% year-over-year to $54.9 billion. This growth was primarily driven by increased branded and specialty pharmaceutical sales within its Pharmaceutical and Specialty Solutions segment. While GAAP operating earnings saw a decline primarily due to litigation charges and goodwill impairment, the company's non-GAAP operating earnings showed significant improvement, increasing by 10% to $666 million. This highlights the company's operational performance excluding certain non-recurring or significant charges. Despite ongoing challenges, including significant litigation expenses and a goodwill impairment charge related to the GMPD segment, Cardinal Health demonstrated strong operational execution. The company's strategic acquisition of Specialty Networks for $1.2 billion aims to enhance its data analytics capabilities and expand its offerings in key therapeutic areas. However, investors should note the upcoming non-renewal of contracts with OptumRx, which represented 16% of fiscal year 2023 revenue, posing a significant headwind for fiscal year 2025. The company is actively managing its capital through share repurchases and dividends while maintaining adequate liquidity.
Financial Highlights
49 data points| Revenue | $54.87B |
| Cost of Revenue | $52.93B |
| Gross Profit | $1.94B |
| SG&A Expenses | $1.27B |
| Operating Income | $369.00M |
| Interest Expense | $28.00M |
| Net Income | $261.00M |
| EPS (Basic) | $1.07 |
| EPS (Diluted) | $1.07 |
| Shares Outstanding (Basic) | 243.00M |
| Shares Outstanding (Diluted) | 245.00M |
Key Highlights
- 1Revenue increased by 9% to $54.9 billion for the three months ended March 31, 2024, driven by the Pharmaceutical and Specialty Solutions segment.
- 2Non-GAAP operating earnings grew by 10% to $666 million for the quarter, indicating improved underlying business performance.
- 3GAAP operating earnings decreased by 36% to $367 million, largely impacted by litigation charges and a $90 million goodwill impairment.
- 4Acquisition of Specialty Networks for $1.2 billion completed in March 2024 to expand data analytics and biopharma offerings.
- 5Significant impact from the upcoming non-renewal of pharmaceutical distribution contracts with OptumRx, which accounted for 16% of FY2023 revenue, expected to impact FY2025 results.
- 6Cash and equivalents stood at $3.7 billion, with $1.7 billion in net cash provided by operating activities for the nine months ended March 31, 2024.
- 7The company returned $750 million to shareholders through share repurchases and paid $377 million in dividends during the nine months ended March 31, 2024.